Last revised by Andrew Murphy on 3 Apr 2020

SeHCAT™ (23-seleno-25-homo-tauro-cholic acid or tauroselcholic acid) is a radiopharmaceutical used in the investigation of bile salt malabsorption, which is a cause of chronic diarrhea. 


  • physical half-life: 118 days

Uses, dosage and timings

A capsule containing SeHCAT is ingested with water. The patient is scanned using a gamma camera 2-3 hours after ingesting the capsule. The patient is rescanned after 7 days and the percentage of retention is calculated.

More than 15% retention is normal and mitigates against a diagnosis of bile salt malabsorption. 

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.